Stallion India Fluorochemicals Q1 FY27: Revenue up 12.78%, PAT grows 79.15%
Stallion India Fluorochemicals reported Q1 FY27 revenue of ₹124.68 crore (up 12.78% YoY) and PAT of ₹18.57 crore (up 79.15% YoY). Key projects include a high-purity helium plant commencing next quarter, Mambattu facility by year-end, and R32 plant by Dec 2026. The company maintains a 30-35% revenue CAGR guidance.
The announcement details strong financial performance, progress on major capacity expansion projects (helium, R32, Mambattu), and reaffirmed growth guidance, which are all material factors for investors and significantly impact the company's valuation and future prospects.
The company reported strong year-on-year growth in revenue and significant improvements in EBITDA and PAT. The update also highlighted progress on key expansion projects and reaffirmed future growth guidance, indicating positive business momentum.
Stallion India Fluorochemicals Limited announced its Q1 FY27 results, reporting a total revenue of ₹124.68 crore, a year-on-year growth of 12.78%. The company's EBITDA increased by 75.85% to ₹25.27 crore, while Profit After Tax (PAT) grew by 79.15% to ₹18.57 crore. This significant improvement in profitability was attributed to better product mix and operational efficiencies.
Key operational developments include the completion of preparations for the high-purity helium processing plant at the Khalapur facility, with an installed capacity of 1200 metric tons per annum. Commercial operations are expected to commence in the next quarter, targeting sectors like semiconductors, electronics, healthcare, and aerospace.
The Mambattu facility in Andhra Pradesh is progressing as planned, with commencement expected by the end of the year. This facility will enhance the company's presence in South India, adding capacity for refrigerant de-bulking, blending, and storage, and will also function as an HFO blending plant.
Furthermore, the 10,000 metric ton R32 manufacturing facility at Bhilwara is on track for completion by the end of December 2026. This project is crucial for backward integration, aiming to reduce dependence on external sourcing and improve supply reliability and margins.
The company reaffirmed its guidance of 30-35% revenue CAGR over the next three years. It also anticipates an improvement in EBITDA margins by 3-4% over the medium term as the contribution from backward integration and higher-value specialty gases increases.
The transcript of the Investor Conference held on August 17, 2026, with regard to the business and financial performance for the quarter ended June 30, 2026, has been uploaded on the company's website.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.